Zopapogene imadenovec
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Dosing in kidney impairment
This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.
Preparation and administration
Prepare this dose
Your numbers for zopapogene imadenovec. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Preparation and Handling PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy. Follow universal biosafety precautions for handling. PAPZIMEOS is provided as a single-dose vial of sterile frozen suspension. PAPZIMEOS MUST BE RAPIDLY thawed before use and prepared for immediate administration . Once thawed, DO NOT place the PAPZIMEOS vial in a refrigerator, freezer, or on dry ice.
Protect PAPZIMEOS from light. DO NOT shake the vial. Recommended Supplies and Materials Freezer for storage of PAPZIMEOS at temperature ≤ -60°C [≤ -76°F] Water bath or dry bead bath set to 37°C [98.6°F] 3 mL sterile syringe Sterile needle (18G to 22G without a filter) to withdraw PAPZIMEOS from the vial Sterile needle for subcutaneous injection (23G to 25G needle, 1/2 - 5/8 inch long) 70% isopropyl alcohol pads Receipt of PAPZIMEOS PAPZIMEOS is provided as a sterile, frozen suspension that has been aseptically filled into single-dose vials fitted with a rubber stopper and aluminum flip-cap seal.
Each vial is sealed inside a pouch, which is placed in the carton along with a Package Insert. The PAPZIMEOS carton is shipped frozen at ≤ -60°C [≤ -76°F] in an insulated shipping box containing dry ice. On receipt, the PAPZIMEOS carton must be stored in a freezer at ≤ -60°C [≤ -76°F]. Preparation of PAPZIMEOS for Injection Remove the carton of PAPZIMEOS from the freezer when ready for administration.
Take the vial out of the pouch and immediately thaw in a 37°C [98.6°F] water bath or dry bead bath with the vial in an upright position until there are no visible ice crystals in the vial. Exposure of the thawed vial to the 37°C [98.6°F] water bath or dry bead bath should be less than or equal to 5 minutes. Immediately after thawing, wipe the vial with 70% isopropyl alcohol.
Flip off the cap and wipe the rubber stopper top. Swirl gently and visually inspect the vial of PAPZIMEOS. PAPZIMEOS should appear as a slightly opalescent to opalescent, colorless liquid, and free of visible particulates. DO NOT use if particulates or discoloration are visible in the suspension. Aseptically withdraw 1 mL of PAPZIMEOS from the thawed vial using a 3 mL syringe with an 18G to 22G needle.
DO NOT use a filter needle. Replace the 18G to 22G needle with a subcutaneous injection needle (23G to 25G). Dispose of the used needle and empty vial in a biohazard container. DO NOT hold PAPZIMEOS at room temperature for more than 60 minutes after thawing. DO NOT store thawed PAPZIMEOS vials or filled syringes in a refrigerator, freezer, or on dry ice.
Treat any PAPZIMEOS spills with a virucidal agent (such as sodium hypochlorite with 0.5% active chlorine or 6% hydrogen peroxide) for 15 minutes. Dispose of any unused product or waste materials as per facility biohazard waste disposal procedure.
Administration Administer PAPZIMEOS via subcutaneous injection with the following procedures: Select the lateral regions of the upper arm and thigh for injection. Avoid areas of edema, potential infection, wounds, scars, or the site of a recent subcutaneous injection. Clean the injection site thoroughly with an alcohol swab and allow at least 30 seconds to dry.
Inject PAPZIMEOS by inserting the needle at an angle to ensure delivery in the subcutaneous space. Clean the area with an alcohol swab again, DO NOT massage the site of injection. Place potentially contaminated materials from the injection site, including dressings, that may have the patient's bodily fluids/waste, in a sealable bag and dispose into regular trash.
These precautions should be followed for 1-2 weeks after injection. Practice proper hand hygiene, such as hand washing, when coming into direct contact with patient body waste. Avoid direct contact with the injection site (e.g., touching or scratching) and dressings for approximately 24 hours following treatment.
Contraindications
None. None. ( 4 )
Pregnancy and lactation
Pregnancy
8.1 Pregnancy Risk Summary There are no available data with PAPZIMEOS in pregnant women. Animal reproductive and developmental toxicity studies have not been conducted with PAPZIMEOS. In the PRGN-2012-201 study, one patient reported pregnancy at 6 months following completion of treatment with PAPZIMEOS. The patient delivered at 40 weeks without any reported birth complications or neonatal concerns. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.